
William R. Schelman
Articles
-
4 weeks ago |
accp1.onlinelibrary.wiley.com | Martha Gonzalez |Martha González |Zhao Yang |William R. Schelman |Thomas C. Marbury
Introduction Fruquintinib (FRUZAQLATM) is a highly selective, oral, small-molecule tyrosine kinase inhibitor of all three vascular endothelial growth factor receptors (VEGFRs), -1, -2, and -3.1, 2 Fruquintinib was initially approved in China for the treatment of metastatic colorectal cancer (mCRC) in patients who had failed two prior lines of systemic therapy.3, 4 It was then approved in the United States in November 2023 for the treatment of adult patients with mCRC who have been previously...
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →